| Non-Small Cell Lung Cancer |
1 |
1 |
| Lung Cancer |
0 |
0.95 |
| Surgery |
0 |
0.86 |
| Neoadjuvant Therapy |
0 |
0.26 |
| Tumor |
0 |
0.26 |
| Small Cell Lung Cancer |
0 |
0.18 |
| Biologic Therapy |
0 |
0.17 |
| Cancer |
0 |
0.17 |
| Chemotherapy |
0 |
0.17 |
| Toxicology |
0 |
0.15 |
| Adverse Effects |
0 |
0.09 |
| Anaplastic Lymphoma Kinase |
0 |
0.09 |
| Food and Drug Administration (FDA) |
0 |
0.09 |
| Immunotherapy |
0 |
0.09 |
| Lung |
0 |
0.09 |
| Ohio |
0 |
0.09 |
| Perioperative Care |
0 |
0.09 |
| Platinum |
0 |
0.09 |
| Patient Safety |
0 |
0.07 |